Cellpro receives investigational device exemption (IDE) for Ceprate trials
This article was originally published in Clinica
Cellpro has received an investigational device exemption from the US FDA to begin clinical trials of its Ceprate T-cell depletion (TCD) system. Ceprate TCD complements the company's Ceprate stem cell concentration (SC) system. It reduces the number of T-lymphocytes in peripheral blood stem cells used when transplanting tissues to a patient from a donor of different histocompatibility.